Bivalent COVID vaccine efficacy at 6 months: 24% against hospitalization, strong against death | CIDRAP
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
New Omicron-specific vaccines offer similar protection to existing boosters
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
COMPARISON OF COVID 19 VACCINES | Mya Care
Evidence to recommendation Framework: Bivalent COVID-19 vaccine booster doses
Potentially breaking the COVID-19 stalemate with variant booster, bivalent or polyvalent vaccines
Efficacy of Bivalent Boosters Against Severe Omicron | Latest news for Doctors, Nurses and Pharmacists | Respirology
Bivalent mRNA booster effective, 'essential' for older adults
Updated Bivalent Boosters Offer Extra Protection Against COVID-19
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Who Is Eligible for a COVID-19 Booster?
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
Comparing the COVID-19 Vaccines: How Are They Different? > News > Yale Medicine
FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN
Vaccine safety and efficacy : Oregon Health News Blog
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial - The Lancet Respiratory Medicine
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases
